Vladimir Coric MD

Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology, and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma.

He has conducted numerous clinical trials in various illnesses including obsessive-compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma.

Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identify and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma.

Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association).

Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.